Vincerx Pharma Inc [VINC] stock prices are up 19.63% to $5.18 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VINC shares have gain 34.90% over the last week, with a monthly amount glided 335.29%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, January 2024, Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma. In a post published today on Yahoo Finance, Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone.
From an analyst’s perspective:
Vincerx Pharma Inc [NASDAQ: VINC] stock has seen the most recent analyst activity on January 14, 2022, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $25. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on December 23, 2021, and set its price target to $25. On November 01, 2021, SVB Leerink initiated with a Outperform rating and assigned a price target of $24 on the stock. Laidlaw started tracking the stock assigning a Buy rating and suggested a price target of $30 on September 13, 2021. B. Riley Securities initiated its recommendation with a Buy and recommended $26 as its price target on August 25, 2021.
The stock price of Vincerx Pharma Inc [VINC] has been fluctuating between $0.61 and $4.44 over the past year. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Vincerx Pharma Inc [NASDAQ: VINC] shares were valued at $5.18 at the most recent close of the market. An investor can expect a potential drop of -22.78% based on the average VINC price forecast.
Analyzing the VINC fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.52, Equity is -1.31 and Total Capital is -3.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.40 points at the first support level, and at 3.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.81, and for the 2nd resistance point, it is at 6.44.
Vincerx Pharma Inc [VINC] reported earnings per share of -$0.46 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.46/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.52 per share as compared to estimates of -$0.6 per share, a difference of $0.08 representing a surprise of 13.30%.
Ratios To Look Out For
It’s worth pointing out that Vincerx Pharma Inc [NASDAQ:VINC]’s Current Ratio is 2.58. Also, the Quick Ratio is 2.58, while the Cash Ratio stands at 1.7.
Transactions by insiders
Recent insider trading involved Seelenberger Alexander A.,, that happened on Aug 11 when 10500.0 shares were purchased., Hamdy Ahmed MD completed a deal on Aug 10 to buy 5400.0 shares. Meanwhile, THOMAS TOM C bought 5000.0 shares on Aug 10.
